Affiliations: Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China
Correspondence:
[*]
Corresponding author: Huaxi Xu, Department of Immunology, School of Medicine, Jiangsu University, Xuefu Road, Zhenjiang 212013, Jiangsu, China. E-mail:xuhx@ujs.edu.cn
Abstract: BACKGROUND: ADP-ribosylation factor (ARF)-like 4c (Arl4c) has been reported
to promote tumorigenesis in colorectal and lung cancers and may represent a
novel therapeutic target. The aim of this study was to investigate the
expression of ADP-ribosylation factor (ARF)-like 4c (Arl4c) in colorectal
cancer (CRC) in Chinese populations and an AOM/DSS-induced mouse colorectal
carcinogenesis model, and its prognostic value in patients with CRC. MATERIALS AND METHODS: Expression of Arl4c in CRC patients and
AOM/DSS-induced colorectal tumors was detected using immunohistochemistry
and real- Real time PCR. In addition, the correlations between Arl4c
expression and clinicopathological characteristics and overall survival were
evaluated using Kaplan-Meier analysis. RESULTS: The Arl4c was statistically
significantly overexpressed in CRC tissues relative to adjacent normal
tissue (p= 0.001). CRC patients with high Arl4c expression tended to show
poorer survival than patients with lower Arl4c expression (p= 0.069).
However, the level of Arl4c expression was not visibly correlated with age,
gender or tumor stage. In addition, increased expression of Arl4c was also
found in AOM/DSS-induced colorectal tumors (p= 0.001), which indicated that
Arl4c might play an important role in colon tumorigenesis. CONCLUSIONS: Results indicated that overexpression of Arl4c might contribute
to the tumorigenesis and might play a pivotal role in the progression of CRC.
